Drug Profile
Research programme: RNA-based therapeutics - Janssen Vaccines and Prevention/Viridos
Alternative Names: Cancer therapeutics - Janssen Vaccines & Prevention B.V./Viridos; Infectious disease RNA-based therapeutics - Janssen Vaccines & Prevention B.V./Viridos; RNA-based medicines - Janssen Vaccines & Prevention B.V./Viridos; RNA-based therapies - Janssen Vaccines & Prevention B.V./Viridos; RNA-based vaccines - Janssen Vaccines & Prevention B.V./ViridosLatest Information Update: 29 Sep 2021
Price :
$50
*
At a glance
- Originator Synthetic Genomics
- Developer Janssen Vaccines and Prevention B.V; Viridos
- Class Anti-infectives; Antineoplastics; RNA vaccines
- Mechanism of Action Immunostimulants; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Infections
Most Recent Events
- 27 Sep 2021 Synthetic Genomics is now called Viridos
- 28 Feb 2021 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 28 Feb 2021 No recent reports of development identified for research development in Infections in USA (Parenteral)